Skip to main content
Premium Trial:

Request an Annual Quote

Arrays: Going Like Hotcakes

Today's Wall Street Journal includes an article ($) looking into the growing price war between Affymetrix and Illumina. Citing the value of the current array market as somewhere between $200 million and $350 million with projected growth rates of 25 percent to 40 percent, the WSJ says that as a result of "a big misstep last year," Affy has essentially "handed the hottest part of the market to its nimble young rival, Illumina."

That misstep -- the release of what WSJ calls an "under-tested" 500K SNP chip -- eventually forced Affy to slash prices in an effort to win back the marketshare gained by Illumina in the interim. Sales are already up, and the end result of the skirmish might actually be increased use of arrays on all fronts.

 

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.